Pharmacovigilance Considerations for Biosimilars in the USA

BioDrugs

Volumn 29, Issue 5, 2015, Pages 309-321

  Grampp, Gustavo ^a   Felix, Thomas ^a,b  

^a AMGEN INC   (United States)

^b Amgen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT;

DRUG APPROVAL; DRUG INDUSTRY; DRUG LEGISLATION; DRUG NOMENCLATURE; DRUG QUALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; OUTPATIENT; PATIENT SAFETY; PHARMACY; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; SIGNAL DETECTION; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BIOSIMILAR PHARMACEUTICALS; HUMANS; PHARMACOVIGILANCE; UNITED STATES;

EID: 84946090981     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-015-0137-2     Document Type: Review

References (55)

1. US Food and Drug Administration. FDA approves first biosimilar product Zarxio. US Food and Drug Administration. 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm. Accessed 1 July 2015.
2. US Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Rockville: US Food and Drug Administration; 2015.
3. Felix T, Johansson TT, Colliatie JA, Goldberg MR, Fox AR. Biologic product identification and US pharmacovigilance in the biosimilars era. Nat Biotechnol. 2014;32(2):128-30.
4. Casadevall N, Felix T, Strober BE, Warnock DG. Similar names for similar biologics. BioDrugs. 2014;28(5):439-44.
5. Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, et al. Pharmacovigilance and biosimilars: considerations, needs, and challenges. Expert Opin Biol Ther. 2013;13(7):1039-47.
6. Zuniga L, Calvo B. Biosimilars: pharmacovigilance and risk management. Pharmacoepidemiol Drug Saf. 2010;19(7):661-9.
7. Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. N Engl J Med. 2011;365(5):385-8.
8. Drug Quality and Security Act, Public Law 113-54. 2013. http://www.gpo.gov/fdsys/pkg/PLAW-113publ54/content-detail.html. Accessed 6 July 2015.
9. Haerian K, Varn D, Vaidya S, Ena L, Chase HS, Friedman C. Detection of pharmacovigilance-related adverse events using electronic health records and automated methods. Clin Pharmacol Ther. 2012;92(2):228-34.
10. US Food and Drug Administration. Guidance for industry: E2E pharmacovigilance planning. US Food and Drug Administration. 2005. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance/ucm073107.pdf. Accessed 27 Oct 2014.
11. US Food and Drug Administration. How consumers can report an adverse event or serious problem to the FDA. US Food and Drug Administration. 2014. http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053074.htm. Accessed 27 Oct 2014.
12. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment. Rockville: US Food and Drug Administration; 2005.
13. Pfizer. What is a safety signal? Pfizer. 2011. http://www.pfizer.com/files/health/medicine-safety/2-4-What-is-a-Safety-Signal.pdf. Accessed 9 Mar 2015.
14. Robinson S, Pool R, Giffin R. Emerging safety science: workshop summary. Washington, DC: National Academies Press; 2008.
15. Platt R, Madre L, Reynolds R, Tilson H. Active drug safety surveillance: a tool to improve public health. Pharmacoepidemiol Drug Saf. 2008;17(12):1175-82.
16. Vermeer NS, Straus SM, Mantel-Teeuwisse AK, Domergue F, Egberts TC, Leufkens HG, et al. Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases. Drug Saf. 2013;36(8):617-25.
17. US Food and Drug Administration. Guidance for industry: postmarketing safety reporting for human drug and biological products including vaccines. US Food and Drug Administration. 2001. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm092257.pdf. Accessed 27 Oct 2014.
18. US Food and Drug Administration. CDER MAPP 5240.8: Handling of adverse experience reports and other generic drug postmarketing reports. US Food and Drug Administration. 2005. http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/UCM079791.pdf. Accessed 27 Oct 2014.
19. US Food and Drug Administration. Quarterly data extract from the Adverse Event Reporting System (AERS). US Food and Drug Administration. 2011. http://www.docstoc.com/docs/159969837/FDA-Asc-nts-database-description-ument. Accessed 27 Oct 2014.
20. Casadevall N. Immune-response and adverse reactions: PRCA case example. European Medicines Agency. 2009. http://www.ema.europa.eu/docs/en-GB/document-library/Presentation/2009/11/WC500011064.pdf. Accessed 26 Feb 2015.
21. Purcell RT, Lockey RF. Immunologic responses to therapeutic biologic agents. J Investig Allergol Clin Immunol. 2008;18(5):335-42.
22. Lietzan EF, Sim LE, Alexander EA. Biosimilar naming: how do adverse event reporting data support the need for distinct nonproprietary names for biosimilars? Food Drug Policy Forum. 2013;3(6):1-24.
23. Government Accountability Office. Food and Drug Administration response to heparin contamination helped protect public health; controls that were needed for working with external entities were recently added. Washington, DC: Government Accountability Office; 2010.
24. US Food and Drug Administration. Information on adverse event reports and heparin. US Food and Drug Administration. 2009. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM112669. Accessed 29 Sept 2015.
25. Wetterhall SF, Noji EK. Surveillance and epidemiology. In: Noji EK, editor. The public health consequences of disasters. New York: Oxford University Press; 1997. p. 37-64.
26. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel system - a national resource for evidence development. N Engl J Med. 2011;364(6):498-9.
27. Schneider G, Kachroo S, Jones N, Crean S, Rotella P, Avetisyan R, et al. A systematic review of validated methods for identifying anaphylaxis, including anaphylactic shock and angioneurotic edema, using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21(s1):240-7.
28. Bohlke K, Davis RL, DeStefano F, Marcy SM, Braun MM, Thompson RS. Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. J Allergy Clin Immunol. 2004;113(3):536-42.
29. Huang F, Chawla K, Jarvinen KM, Nowak-Weegrzyn A. Anaphylaxis in a New York City pediatric emergency department: triggers, treatments, and outcomes. J Allergy Clin Immunol. 2012;129(1):162-8.
30. Johannes CB, Ziyadeh N, Seeger JD, Tucker E, Reiter C, Faich G. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation. Drug Saf. 2007;30(8):705-13.
31. Olson K. Alliance for Safe Biologic Medicines - prescriber survey. Alliance for Safe Biologic Medicines. 2012. http://safebiologics.org/resources/wp-content/uploads/2012/09/ASBM-Survey-2.pdf. Accessed 27 Oct 2014.
32. Stergiopoulos S, Brown CA, Grampp G, Felix T, Getz KA. Identifying and quantifying the accuracy of product name attribution of US-sourced adverse event reports in MedWatch of somatropins and insulins. Ther Innov Regul Sci. 2015;9(5):706-16.
33. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use, L 348/74 (2010). Official Journal of the European Union. 2010. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0074:0099:EN:PDF. Accessed 31 Aug 2015.
34. Amgen Inc. Docket nos. FDA-2013-P-1153; FDA-2013-P-1398, respectively, non-proprietary naming of biosimilars. 2015. http://www.regulations.gov/#!documentDetail;D=FDA-2013-P-1398-0022. Accessed 10 Sept 2015.
35. Steinman MA, Chren MM, Landefeld CS. What's in a name? Use of brand versus generic drug names in United States outpatient practice. J Intern Med. 2007;22(5):645-8.
36. US Food and Drug Administration. Guidance for industry: nonproprietary naming of biological products. Rockville, MD. 2015.
37. World Health Organization. Biological qualifier: an INN proposal. World Health Organization. 2014. http://www.who.int/medicines/services/inn/bq-innproposal201407.pdf?ua=1. Accessed 27 Oct 2014.
38. US Food and Drug Administration. Code of Federal Regulations. 21CFR § 201.2 Drugs and devices; National Drug Code numbers. US Food and Drug Administration. 2012. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=201.2. Accessed 29 Sept 2015.
39. US Food and Drug Administration. Instructions for completing form FDA 3500. US Food and Drug Administration. 2013. http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/ucm149236.htm. Accessed 8 July 2014.
40. US Food and Drug Administration. Form FDA 3500. US Food and Drug Administration. 2013. http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM163919.pdf. Accessed 5 Aug 2014.
41. Centers for Disease Control and Prevention, US Food and Drug Administration. Vaccine Adverse Event Reporting System. US Food and Drug Administration. 2014. https://vaers.hhs.gov/index. Accessed 1 July 2015.
42. Goldman GS, Miller NZ. Relative trends in hospitalizations and mortality among infants by the number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990-2010. Hum Exp Toxicol. 2012;31(10):1012-21.
43. National Institute of Standards and Technology. NIST NCPDP initial assessment: standards compatability in medication reconciliation. National Institute of Standards and Technology. 2011. http://healthcare.nist.gov/resources/docs/FirstAmerican/NIST-NCPDPStandardsCompatibilityMedRec.pdf. Accessed 6 Aug 2014.
44. Hennessy S, Leonard CE, Platt R. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States. Clin Pharmacol Ther. 2010;87(2):157-9.
45. Getz KA, Stergiopoulos S, Kaitin KI. Evaluating the completeness and accuracy of MedWatch data. Am J Ther. 2014;21(6):442-6.
46. DiMartino LD, Curtis LH, Williams RL, Abernethy DR, Schulman KA. Using Medicare administrative data to conduct postmarketing surveillance on follow-on biologics: issues and opportunities. Food Drug Law J. 2008;63:891-900.
47. Grampp G, Bonafede M, Felix T, Li E, Malecki M, Sprafka JM. Active and passive surveillance of enoxaparin generics: a case study relevant to biosimilars. Expert Opin Drug Saf. 2015;14(3):349-60.
48. Centers for Medicare and Medicaid Services. Medicare program: hospital outpatient prospective payment and ambulatory surgical center payment systems and quality reporting programs; short inpatient hospital stays; transition for certain medicare-dependent, small rural hospitals under the hospital inpatient prospective payment system. Centers for Medicare and Medicaid Services. 2015. https://www.federalregister.gov/articles/2015/07/08/2015-16577/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment. Accessed 16 July 2015.
49. Yesner DL. Where will biosimilars fit in federal drug pricing programs. In: Pharmaceutical Law & Industry Report. Morgan Lewis & Bockius LLP. 2011. http://www.morganlewis.com/pubs/where-will-biosimilars-fit-in-federal-drug-pricing-programs-bnas-ipharmaceutical-law-industry-reporti. Accessed 24 Sept 2014.
50. Social Security Administration. Section 1847A: use of average sales price payment methodologies. Social Security Administration. http://www.ssa.gov/OP-Home/ssact/title18/1847A.htm. Accessed 8 Sept 2014.
51. US Food and Drug Administration. Guidance for industry: biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. Rockville: US Food and Drug Administration; 2015.
52. State of Delaware. State Bill 118. An act to amend Title 24 of the Delaware code relating to pharmacists. State of Delaware. 2014. http://legis.delaware.gov/LIS/lis147.nsf/vwLegislation/SS+1+FOR+SB+118/$file/legis.html?open. Accessed 1 July 2015.
53. State of Massachusetts. Bill H.3734: an act relative to the substitution of interchangeable biosimilars. State of Massachusetts. 2014. https://malegislature.gov/Bills/188/House/H3734/History. Accessed 5 Aug 2014.
54. Federal Register, Vol 77, No. 95, 2012. http://www.gpo.gov/fdsys/pkg/FR-2012-05-16/pdf/2012-11543.pdf. Accessed 8 Sept 2014.
55. Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, et al. The US Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21(S1):S1-8.